Should we use the oral selective IP receptor agonist selexipag off-label in children with pulmonary arterial hypertension?

Pulm Circ. 2018 Jul-Sep;8(3):2045894018793580. doi: 10.1177/2045894018793580.


We discuss the currently available data on the use of the prostacyclin mimetic selexipag in children and adolescents with pulmonary arterial hypertension (PAH). Future indications may include transitioning from intravenous prostacyclin/prostacyclin analog to oral selexipag, and vice versa, or adding selexipag as a third oral PAH-targeted agent in children not responding well to dual PAH therapy.

Keywords: Pediatric; prostacyclin receptor agonist; pulmonary arterial hypertension; selexipag.